YUMAB cooperates with AI specialist
YUMAB and MOLCURE collaborate to advance zero-shot AI antibody discovery technology for undruggable targets
YUMAB GmbH, a antibody discovery CRO headquartered in Braunschweig, Germany, and MOLCURE Inc., an AI-driven drug discovery company based in Kawasaki, Japan, announced their on-going collaboration now includes advancing the application of zero-shot AI technology for antibody discovery. The collaboration brings together complementary expertise and technologies. MOLCURE has a decade of experience in AI-design of antibodies and has accumulated over a billion proprietary experimental data points, and YUMAB has more than thirty years of technical excellence and research in antibody discovery, engineering and manufacturing.
YUMAB and MOLCURE share a common vision to push the boundaries of antibody discovery for difficult to drug protein classes that are of high therapeutic potential, such as G protein-coupled receptors (GPCRs) and ion channels. These proteins are often challenging to screen with conventional methods, including animal immunization and display screening. In these physical screening systems, many factors can result in the target protein and/or antibodies not being expressed or not in pathophysiological conformations, causing a failure to identify potentially therapeutic antibodies.
YUMAB and MOLCURE are collaborating on zero-shot AI technology to overcome the barriers of conventional screening methods for undrugged targets. Zero-shot AI technology enables the in silico de novo design of antibody sequences based on antigen sequences and/or target structures. This de novo design of antibodies, which does not require initial physical screening to identify starting points, will expand the types of targets that can be drugged and increase the diversity of antibody sequences for each target.
In the collaboration, MOLCURE is using its proprietary zero-shot AI technology to design antibody sequences and is also applying both physics-based methods, such as molecular dynamics, and additional AI algorithms for accuracy improvement. YUMAB then draws on its deep expertise and technology to express the designed antibody sequences and perform experimental measurements. The data that is generated is incorporated into the AI for further iteration and optimization of antibody design.
“We’re excited about the progress we have made in our collaboration with MOLCURE and their AI technology,” said Dr. Thomas Schirrmann, CEO, YUMAB. “Once zero-shot AI technology is fully developed, it will give clients the opportunity to explore a much larger and more diverse sequence space than can be physically generated in conventional screening, which will translate into better antibodies for more targets, and significant savings in time and money.”
“YUMAB is the ideal partner to ensure that we maximize the number of zero-shot designed antibodies that are made and tested, and we’ve been impressed by the outcomes of the collaboration” said Dr. Satoshi Tamaki, CEO/CSO, MOLCURE. “Our goal is to utilize zero-shot AI technology to deliver next-generation antibodies to as many patients as possible.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
